The bill amends sections 3902.50 and 3902.70 of the Revised Code and enacts a new section 3902.72, which prohibits drug manufacturers from engaging in certain actions regarding reimbursements to 340B covered entities. Specifically, it prevents manufacturers, repackagers, and third-party logistics providers from denying or limiting the acquisition and delivery of 340B drugs to grantees, as well as from requiring claims or utilization data as a condition for such transactions. The bill also establishes definitions for terms related to the 340B drug pricing program and outlines penalties for violations, including civil penalties and potential referral to the state board of pharmacy.

Additionally, the bill updates the numbering of sections, replacing the old section 3902.72 with 3902.75, and repeals the existing sections 3902.50, 3902.70, and 3902.72. It introduces new definitions and clarifies the responsibilities of health plan issuers and pharmacy benefit managers in providing data related to drug coverage and cost-sharing. The provisions of the new section 3902.72 are set to take effect on January 1, 2022.

Statutes affected:
As Introduced: 3902.50, 3902.70, 3902.72, 3902.75